



(86) Date de dépôt PCT/PCT Filing Date: 2007/02/02
(87) Date publication PCT/PCT Publication Date: 2007/08/16
(85) Entrée phase nationale/National Entry: 2008/08/05
(86) N° demande PCT/PCT Application No.: EP 2007/051017
(87) N° publication PCT/PCT Publication No.: 2007/090793
(30) Priorité/Priority: 2006/02/06 (US60/765,166)

(51) Cl.Int./Int.Cl. *C07D 233/50* (2006.01),
A61K 31/41 (2006.01), *A61K 31/495* (2006.01),
A61P 29/00 (2006.01), *A61P 9/00* (2006.01),
C07D 239/76 (2006.01)

(71) Demandeurs/Applicants:

NICOX S.A., FR;
PFIZER INC., US


(72) Inventeurs/Inventors:

BENEDINI, FRANCESCA, IT;
IMPAGNATIELLO, FRANCESCO, IT;
BIONDI, STEFANO, IT;
ONGINI, ENNIO, IT;
CHONG, WESLEY KWAN MUNG, US


(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : DERIVES D'APRACLONIDINE ET DE BRIMODNIDINE COMPRENANT DES GROUPES NITROOXY COMME AGONISTES DES RECEPTEURS ALPHA 2-ADRENERGIQUES

(54) Title: NITROOXY-COMPRISING DERIVATIVES OF APRACLONIDINE AND BRIMODNIDINE AS ALPHA2-ADRENERGIC RECEPTOR AGONISTS



(Ia)



(Ib)

(57) Abrégé/Abstract:

The present invention relates to alpha2-adrenergic receptor agonist nitrooxyderivatives of formula (I), wherein A is selected from (Ia) or (Ib) having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of ocular diseases, in particular high intraocular pressure and glaucoma. A-X₁-Y-ONO₂ (I)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2007 (16.08.2007)

PCT

(10) International Publication Number
WO 2007/090793 A1

(51) International Patent Classification:

C07D 233/50 (2006.01) *A61K 31/495* (2006.01)
C07D 239/76 (2006.01) *A61P 9/00* (2006.01)
A61K 31/41 (2006.01) *A61P 29/00* (2006.01)

(milano) (IT). **CHONG, Wesley Kwan Mung** [US/US];
2105 Coolngreen Way, Encinitas, CA 92024 (US).

(74) **Agent: BARCHIELLI, Giovanna**; Nicox Research Institute Srl, Via L. Ariosto 21, I-20091 Bresso (milano) (IT).

(21) International Application Number:

PCT/EP2007/051017

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) **International Filing Date:** 2 February 2007 (02.02.2007)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) Priority Data:

60/765,166 6 February 2006 (06.02.2006) US

(71) **Applicants** (*for all designated States except US*): **NICOX S.A.** [FR/FR]; Taissounières Hb4, 1681 Route Des Dolines, Boîte postale 313, F-06560 Sophia Antipolis - Valbonne (FR). **PFIZER INC.** [US/US]; 10555 Science Center Drive, San Diego, CA 92121 (US).

(72) Inventors; and

(75) **Inventors/Applicants** (*for US only*): **BENEDINI, Francesca** [IT/IT]; Via Spilamberto 16, I-20097 San Donato Milanese (milano) (IT). **IMPAGNATIELLO, Francesco** [IT/IT]; Via Venini 64, I-20127 Milano (IT). **BIONDI, Stefano** [IT/IT]; Via Foscolo 35, I-37057 San Giovanni Lupatolo (verona) (IT). **ONGINI, Ennio** [IT/IT]; Via Fratelli Cervi, Residenza Campo, I-20090 Segrate


(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** NITROOXY-COMPRISING DERIVATIVES OF APRACLONIDINE AND BRIMODNIDINE AS α_2 -ADRENERGIC RECEPTOR AGONISTS



(Ia)



(Ib)

(57) **Abstract:** The present invention relates to α_2 -adrenergic receptor agonist nitrooxyderivatives of formula (I), wherein A is selected from (Ia) or (Ib) having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of ocular diseases, in particular high intraocular pressure and glaucoma. A-X₁-Y-ONO₂ (I)

NITROOXY-COMPRISING DERIVATIVES OF APRACLONIDINE AND BRIMODNIDINE AS
ALPHA2-ADRENERGIC RECEPTOR AGONISTS

The present invention relates to alpha₂-adrenergic
5 receptor agonist nitrooxyderivatives and to their use for
the treatment of ocular diseases in particular for the
treatment of high intraocular pressure and glaucoma.

Glaucoma occurs in about 2% of all population over the
age of 40 and may be asymptomatic for years before
10 progressing to rapid loss of vision.

Glaucoma is primarily classified as open-angle,
closed-angle, or congenital, and further classified as
primary and secondary. Glaucoma is treated with a variety
of pharmacological and surgical approaches. In cases where
15 glaucoma is associated with ocular hypertension,
pharmacological treatment comprises adrenergic agonists
(epinephrine, dipevefrin, apraclonidine), cholinergic
agonists (pilocarpine), beta blockers (betaxolol,
levobunolol, timolol), carbonic anhydrase inhibitors
20 (acetazolamide, clorzilamide) or more recently,
prostaglandin analogues (latanoprost, bimatoprost) and
alpha adrenergic agonists (brimonidine, apraclonidine).
These pharmacological approaches help to restore the IOP to
a normotensive state either by inhibiting the production of
25 aqueous humor by the ciliary body, or facilitating aqueous
humor outflow across the trabecular meshwork. In particular
alpha-adrenergic agonists, such as brimonidine and
apraclonidine, control IOP by reducing the production of
aqueous humor as well as enhancing uveoscleral outflow.

30 Alpha₂-adrenergic receptor agonists are also used for
the treatment of ocular hypertension and optic neuropathies
both in monotherapy and as adjunctive therapy to beta-
blockers. They are also used for the prophylactic treatment
of acute pressure rises (i.e. before and after argon laser


trabeculoplasty, cataract surgery, vitrectomy, peripheral
iridotomy, capsulotomy). Their activity is due mainly to
the activation of α_2 -adrenergic receptors in the eye;
such activation leads to reduction of aqueous humor
5 production and increase in uveoscleral outflow. (Curr Opin
Ophthalmol 1997, 8(2); 42-49)

It is known that optical ophthalmic solutions
containing α_2 -adrenergic receptor agonists are absorbed
systemically and can produce side-effects including
10 systemic hypotension, decreased heart rate, dry mouth, lid
retraction, conjunctiva blanching, hyperaemia, burning,
uveitis, tachyphylaxis, posterior segment vasoconstriction,
topical allergy-like syndrome, increased pupil diameter,
depression, anxiety, fatigue, nausea. (Hoyng and van Beek,
15 *Drugs*, 59: 411-434 (2000), *Surv Ophthalmol* 1996, 41 Suppl
1: S19-26)

As described above, agents commonly used to treat
glaucoma may cause adverse effects. Thus, there is a need
for selective α_2 -adrenergic receptor agonists that are
20 both safe and effective in the treatment of ocular diseases
and in particular glaucoma.

It has been surprisingly found that α_2 -adrenergic
receptor agonists nitrooxyderivatives of formula (I) have a
significantly improved overall profile as compared to
25 native compounds with respect to both pharmacological
activity and enhanced tolerability.


It is an object of the present invention α_2 -
adrenergic receptor agonists nitrooxyderivatives of general
formula (I) and pharmaceutically acceptable salts or
30 stereoisomers thereof:




(I)

wherein:

A is selected from



(Ia)




(Ib)

5

X₁ has the following meanings:

-C(O)-, -C(O)O-,



Y is a bivalent radical having the following meanings:

10

a)

- straight or branched C₁-C₂₀ alkylene, preferably C₁-C₁₀, being optionally substituted with one or more of the substituents selected from the group consisting of: halogen atoms, hydroxy, -ONO₂ or T₀, wherein T₀ is


15

-OC(O)(C₁-C₁₀ alkyl)-ONO₂ or -O(C₁-C₁₀ alkyl)-ONO₂;


- cycloalkylene with 5 to 7 carbon atoms into cycloalkylene ring, the ring being optionally substituted with side chains T, wherein T is straight or branched alkyl with from 1 to 10 carbon atoms, preferably CH₃;

20

b)




c)



wherein n is an integer from 0 to 20, preferably n is from 1 to 10, n^1 is an integer from 1 to 20, preferably n^1 is from 1 to 10;

d)

5




wherein:

n^1 is as defined above and n^2 is an integer from 0 to 2;

$X_2 = -OCO-$ or $-COO-$ and R^2 is an hydrogen atom or CH_3 ;

e)

10




wherein:

n^1 , n^2 , R^2 and X_2 are as defined above;

Y^1 is $-CH_2-CH_2-$ or $-CH=CH-(CH_2)_{n^2}-$;

f)

15



wherein:

n^1 and R^2 are as defined above, R^3 is H or $-COCH_3$;

with the proviso that when Y is selected from the bivalent radicals mentioned under b)-f), the $-ONO_2$ group is linked to a $-(CH_2)_{n^1}$ group;

20


g)



wherein X_3 is an oxygen atom or a sulphur atom, preferably X_3 is an oxygen atom;

n^3 is an integer from 1 to 6, preferably from 1 to 4, R^2 is as defined above;

h)



5 wherein:


n^4 is an integer from 0 to 10;

n^5 is an integer from 1 to 10;

R^4 , R^5 , R^6 , R^7 are the same or different, and are H or straight or branched C_1 - C_4 alkyl, preferably R^4 , R^5 , R^6 , R^7


10 are H;

wherein the $-\text{ONO}_2$ group is linked to




wherein n^5 is as defined above;

15 Y^2 is an heterocyclic saturated, unsaturated or aromatic 5 or 6 members ring, containing one or more heteroatoms selected from nitrogen, oxygen, sulfur, and is selected from



20




The term "C₁-C₂₀ alkylene" as used herein refers to
 5 branched or straight chain C₁-C₂₀ hydrocarbon, preferably
 having from 1 to 10 carbon atoms such as methylene,
 ethylene, propylene, isopropylene, n-butylene, pentylene,
 n-hexylene and the like.

The term "C₁-C₁₀ alkyl" as used herein refers to
 10 branched or straight chain alkyl groups comprising one to
 ten carbon atoms, including methyl, ethyl, n-propyl,
 isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, octyl
 and the like.


The term "cycloalkylene" as used herein refers to ring
 15 having from 5 to 7 carbon atoms including, but not limited
 to, cyclopentylene, cyclohexylene optionally substituted
 with side chains such as straight or branched (C₁-C₁₀)-
 alkyl, preferably CH₃.

The term "heterocyclic" as used herein refers to
 20 saturated, unsaturated or aromatic 5 or 6 members ring,
 containing one or more heteroatoms selected from nitrogen,
 oxygen, sulphur, such as for example pyridine, pyrazine,
 pyrimidine, pyrrolidine, morpholine, imidazole and the
 like.


25 Preferred nitrooxyderivatives of formula (I) are:



(1)




(3)




(5)

5




(7)




(9)


(2)




(4)







(6)





(8)




(10)














5




10









(28)



(29)




(30)




(31)


5




(32)




(33)




(34)




(35)




(36)




(37)




(38)




(39)




(40)







(41)





(42)




(43)



5




(48)




(50)

(49)




(51)


5




(52)




(53)




(54)



(55)




(56)




(57)

5




(58)




(59)


10




(60)




(61)




(62)




(63)



(64)



(65)



Another object of the present invention is
5 pharmaceutical compositions containing at least a compound
of the present invention of formula (I) together with non
toxic adjuvants and/or carriers usually employed in the
pharmaceutical field.

The preferred route of administration is topical.

10 The compounds of the present invention can be
administered as solutions, suspensions or emulsions
(dispersions) in an ophthalmically acceptable vehicle. The
term "ophthalmically acceptable vehicle" as used herein
refers to any substance or combination of substances which
15 are non-reactive with the compounds and suitable for
administration to patient.

Preferred are aqueous vehicles suitable for topical
application to the patient's eyes.

Other ingredients which may be desirable to use in the
20 ophthalmic compositions of the present invention include
antimicrobials, preservatives, co-solvents, surfactants and
viscosity building agents.

The invention also relates to a method for treating
glaucoma or ocular hypertension, said method consisting in
25 contacting an effective intraocular pressure reducing
amount of a composition with the eye in order to reduce eye
pressure and to maintain said pressure on a reduced level.

The doses of the compounds of the invention can be determined by standard clinical techniques and are in the same range or less than those described for the corresponding underivatized, commercially available
5 compounds as reported in the: Physician's Desk Reference, Medical Economics Company, Inc., Oradell, N.J., 58th Ed., 2004; The pharmacological basis of therapeutics, Goodman and Gilman, J. G. Hardman, L. e. Limbird, Tenth Ed.

The treatment may be advantageously carried out in
10 that one drop of the composition, corresponding to about 30 µl, is administered about several times per day, for example from 1 to 3 times, to the patient's eye.


It is further contemplated that the compounds of the present invention can be used with other medicaments known
15 to be useful in the treatment of glaucoma or ocular hypertension, either separately or in combination. For example the compounds of the present invention can be combined with (i) beta-blockers, such as timolol, betaxolol, levobunolol and the like (see U.S. Pat. No.
20 4,952,581); (ii) carbonic anhydrase inhibitors, such as brinzolamide.

Also contemplated is the combination with nitrooxy derivatives of the above reported compounds, for example nitrooxy derivatives of beta-blockers such as those
25 described in U.S. Pat. No. 6,242,432.


The compounds of the present invention can be synthesised as follows.

A) The compounds of general formula (I) wherein A is the radical (Ia) or (Ib), X₁ is -C(O)-, and Y is as above
30 defined, can be obtained by a process comprising:

1A) reacting a compound of formula (IIIa) or (IIIb)



(IIIa)



(IIIb)


wherein

P is H or a amino protecting group such as t-butoxycarbonyl
 5 and those described in T. W. Greene "Protective groups in
 organic synthesis", Harvard University Press, 1980;
 with a compound of formula (1a):



(1a)

10 wherein Y are as above defined and wherein Act is a
 carboxylic acid activating group used in peptide chemistry
 such as:



1A.a) removing the protective group of the compounds
 15 obtained in presence of a strong acid, such as HCl in
 dioxane or trifluoroacetic acid, as described in T. W.
 Greene "Protective groups in organic synthesis", Harvard
 University Press, 1980, and optionally converting the
 resulting compound of general formula (I) into a
 20 pharmaceutically acceptable salt thereof.

The reaction of a compound of formula (IIIa) or (IIIb),
 wherein P is as above defined, with a compound of formula
 (1a) wherein Y is as above defined and Act a carboxylic
 acid activating group used in peptide chemistry as above
 25 defined, may be carried out in presence of a inorganic or
 organic base in an aprotic polar/non-polar solvent such as
 DMF, THF, acetone or CH₂Cl₂ at temperatures range between

0°-65°C or in a double phase system H₂O/Et₂O at temperatures range between 20°- 40°C; or in the presence of DMAP and a Lewis acid such as Sc(OTf)₃ or Bi(OTf)₃ in solvents such as DMF, CH₂Cl₂.

5 **1A.b)** The compound of formula (IIIa), wherein P is an hydrogen atom, which is known as apraclonidine is commercially available or can be synthesized as described in US 4,517,199; the compound of formula IIIB, which is known as brimonidine, is commercially available or can be
10 synthesised as according to the method described in US 3,890,319.

1A.c) The compounds of formula (1a) wherein Act is carboxylic acid activating group used in peptide chemistry as above defined, are obtained by reacting the acids (1b)

15 HOOC-Y-ONO_2 (1b)

wherein Y is as above defined, with the commercially available compounds (1c)

Act-H (1c)

wherein Act is as above defined, by conventional
20 esterification reaction with condensing agents as DCC, EDAC.HCl as well known in the literature.

1A.d) The compounds of formula (1b) as above defined are obtained by reacting the commercially available acids of formula (1d)



25 Hal-Y-COOH (1d)

with AgNO₃ in a suitable organic solvent such as acetonitrile or tetrahydrofurane (THF) under nitrogen in the dark at temperatures range between 20° to 80°C; alternatively the reaction with AgNO₃ can be performed
30 under microwave irradiation in solvents such acetonitrile or THF at temperatures in the range between 70-180°C for short time (1-60 min).

2A) Alternatively, the compounds of general formula (I) wherein A is the radical (Ia) or (Ib), X₁ is -C(O)-,


and Y is as above defined, can be obtained by a process comprising:

2A.a) reacting a compound of formula (IIIa) or (IIIb)



wherein

P is H or a amino protecting group such as t-butoxycarbonyl and those described in T. W. Greene "Protective groups in organic synthesis", Harvard University Press, 1980; with a compound of formula (1a'):



wherein Y is as above defined, and then removing the protective group of the compounds obtained as described in 1A.a); and optionally converting the resulting compounds of formula (I) into a pharmaceutically acceptable salt.

The reaction of a compound of formula (IIIa) or (IIIb), wherein P is as above defined, with a compound of formula (1a') wherein Y is as above defined is carried out in presence of a condensing agent as dicyclohexylcarbodiimide (DCC), N'-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDAC) and a catalyst, such as N,N-dimethylamino pyridine (DMAP), or benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and a organic base, such as N-methylmorpholine, N,N-diisopropylamine. The reaction is carried out in an inert organic solvent dry such as N,N'-dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon at a temperature from

-20°C and 40°C. The reaction is completed within a time range from 30 minutes to 36 hours.

2A.b) The compounds of formula (1a') as above defined are obtained by reacting the commercially available acids of
5 formula (1d)




with AgNO₃ in a suitable organic solvent such as acetonitrile or tetrahydrofuran (THF) under nitrogen in the dark at temperatures range between 20° to 80°C;
10 alternatively the reaction with AgNO₃ can be performed under microwave irradiation in solvents such acetonitrile or THF at temperatures in the range between 70-180°C for short time (1-60 min).


2A.c) The compound of formula (IIIa), wherein P is an
15 hydrogen atom, which is known as apraclonidine is commercially available or can be synthesized as described in US 4,517,199; the compound of formula IIIB, which is known as brimonidine, is commercially available or can be synthesised as according to the method described in US
20 3,890,319.

3A) The compounds of general formula (I) wherein A is the radical (Ia) or (Ib), X₁ is -C(O)-, and Y is as above defined, can be obtained by a process comprising:

3A.a) reacting a compound of formula (IIIa) or (IIIb)
25



(IIIa)




(IIIb)

wherein

P is H or a amino protecting group such as t-butoxycarbonyl
30 and those described in T. W. Greene "Protective groups in organic synthesis", Harvard University Press, 1980;

with a compound of formula (1a''):



wherein Y are as above defined and wherein Hal is a
5 chlorine atom or a bromine atom:

3A.b) removing the protective group of the compounds obtained as described in 1A.a), and optionally converting the resulting compound of general formula (I) into a pharmaceutically acceptable salt thereof.

10 The reaction of a compound of formula (IIIa) or (IIIb), wherein P is as above defined, with a compound of formula (1a'') wherein Y and Hal are as above defined, is carried out in presence of a inorganic or organic base in an aprotic polar/non-polar solvent such as DMF, THF, acetone
15 or CH₂Cl₂ at temperatures range between 0°-65°C or in a double phase system H₂O/Et₂O at temperatures range between 20°- 40°C; or in the presence of DMAP and a Lewis acid such as Sc(OTf)₃ or Bi(OTf)₃ in solvents such as DMF, CH₂Cl₂.

3A.c) The compound of formula (IIIa), wherein P is an
20 hydrogen atom, which is known as apraclonidine, is commercially available or can be synthesized as described in US 4,517,199; the compound of formula IIIB, which is known as brimonidine, is commercially available or can be synthesised as according to the method described in US
25 3,890,319.

3A.d) The compounds of formula (1a'') wherein Hal is as above defined, are obtained by reacting the acids (1b)



wherein Y is as above defined, with thionyl or oxalyl
30 chloride, halides of P^{III} or P^V in solvents inert such as toluene, chloroform, DMF, at temperatures range between 20°- 40°C.


3A.e) The compounds of formula (1b) as above defined are obtained by reacting the commercially available acids of formula (1d)




- 5 with AgNO_3 in a suitable organic solvent such as acetonitrile or tetrahydrofuran (THF) under nitrogen in the dark at temperatures range between 20° to 80°C ; alternatively the reaction with AgNO_3 can be performed under microwave irradiation in solvents such as
10 acetonitrile or THF at temperatures in the range between 70 - 180°C for short time (1-60 min).

B) The compounds of general formula (I) wherein A is the radical (Ia) or (Ib), X_1 is $-\text{C}(\text{O})\text{O}-$ and Y is as above defined, can be obtained by a process comprising:

- 15 **1B)** by reacting a compound of formula (IIIa) or (IIIb)




(IIIa)



(IIIb)

wherein


- 20 P is H or a amino protecting group such as t-butoxycarbonyl and those described in T. W. Greene "Protective groups in organic synthesis", Harvard University Press, 1980; with a compound of formula (1a.i)



- 25 wherein Act and Y are as above defined, in presence of a inorganic or organic base/DMAP in an aprotic polar/non-polar solvent such as DMF, THF or CH_2Cl_2 at temperatures range between 0° to 65°C or in a double phase system $\text{H}_2\text{O}/\text{Et}_2\text{O}$ at temperatures range between 20° to 40°C ; or in
30 the presence of DMAP and a Lewis acid such as $\text{Sc}(\text{OTf})_3$ or $\text{Bi}(\text{OTf})_3$ in solvents such as DMF, CH_2Cl_2 ;

and then removing the protective group of the compounds obtained as described in 1A.a); and optionally converting the resulting compounds of formula (I) into a pharmaceutically acceptable salt.

- 5 **1B.a)** The compounds of formula (1a.i) as above defined are obtained by reacting compounds of formula(1e)



with a compounds of formula(1f)



- 10 wherein Y is as above defined, in presence of an inorganic or organic base in an aprotic polar/non-polar solvent such as DMF, THF or CH_2Cl_2 at temperatures range between 0° to 65°C or in a double phase system $\text{H}_2\text{O}/\text{Et}_2\text{O}$ at temperatures range between 20° to 40°C ,

- 15 **1B.b)** The compounds of formula (1f) are obtained by reacting the commercially available compounds of formula HO-Y-Hal (1f') wherein Y and Hal are as above defined, with AgNO_3 in a suitable organic solvent such as acetonitrile or tetrahydrofuran (THF) under nitrogen in the dark at
20 temperatures range between 20° - 80°C ; alternatively the reaction with AgNO_3 can be performed under microwave irradiation in solvents such acetonitrile or THF at temperatures in the range between about 100 - 180°C for time range about 1-60 min.

- 25 The compounds of formula (1f') are commercially available or can be obtained by method well known in the literature;


1B.c) The compounds of formula (1e) as above defined are obtained by reacting compounds of formula (1c)




- 30 wherein Act is as above defined, with phosgene and derivatives such as triphosgene, in the presence of a inorganic or organic base in an aprotic polar/non-polar solvent such as DMF, THF or CH_2Cl_2 at temperatures range between 0° to 65°C .

C) Alternatively, the compounds of general formula (I) wherein A is the radical (Ia) or (Ib), X_1 is $-C(O)O-$ and Y is as above defined, can be obtained by a process comprising:

- 5 **1C)** reacting a compound of formula (IIIa) or (IIIb)




(IIIa)



(IIIb)

wherein

- 10 P is H or a amino protecting group such as t-butoxycarbonyl and those described in T. W. Greene "Protective groups in organic synthesis", Harvard University Press, 1980; with compounds of formula (1a.ii),



- 15 wherein Hal is an halogen atom, preferably is Cl, and Y is as above defined, in presence of a inorganic or organic base/DMAP in an aprotic polar/non-polar solvent such as DMF, THF or CH_2Cl_2 at temperatures range between 0° to $65^\circ C$ or in a double phase system H_2O/Et_2O at temperatures range
20 between 20° to $40^\circ C$; or in the presence of DMAP and a Lewis acid such as $Sc(OTf)_3$ or $Bi(OTf)_3$ in solvents such as DMF, CH_2Cl_2 ; and then removing the protective group of the obtained compounds as described in 1A.a); and optionally converting the resulting compounds of formula (I) into a
25 pharmaceutically acceptable salt.

- 1C.a)** The compound of formula (IIIa), wherein P is an hydrogen atom, which is known as apraclonidine is commercially available or can be synthesized as described in US 4,517,199; the compound of formula IIIB, which is
30 known as brimonidine, is commercially available or can be

synthesised as according to the method described in US 3,890,319.

1C.b) The compounds of formula (1a.ii) as above defined, are obtained by reacting a compounds of formula (1f)

5 HO-Y-ONO₂ (1f)

and phosgene and its derivatives such as triphosgene in the presence of a inorganic or organic base in an aprotic polar/non-polar solvent such as DMF, THF or CH₂Cl₂ at temperatures range between 0° to 65°C,


10 **1C.c)** The compounds of formula (1f) are obtained as described in 1B.b).

D) The compounds of general formula (I) wherein A is the radical (Ia) or (Ib), X₁ is




15 Y is as above defined, can be obtained by a process comprising:

1D) reacting a compound of formula (IIIa) or (IIIb)



(IIIa)




(IIIb)

20

wherein

P is H or a amino protecting group such as t-butoxycarbonyl and those described in T. W. Greene "Protective groups in organic synthesis", Harvard University Press, 1980;

25 with compounds of formula (1a.iii)



wherein Hal is an halogen atom and W₄ is -CH₂- or -CH(CH₃)-, in presence of a inorganic or organic base in an aprotic polar/non-polar solvent such as DMF, THF or CH₂Cl₂ at

temperatures range between 0° to 65°C or in a double phase system H₂O/Et₂O at temperatures range between 20° to 40°C; and then removing the protective group of the obtained compounds as described in 1A.a).

- 5 **1D.a)** The compounds of formula (1a.iii) are obtained by reacting the commercially available haloalkylhalocarbonate of formula (1g)



- wherein Hal and W₄ are as above defined, with a compound of
10 formula (1f)




- wherein Y is as above defined, in the presence of a inorganic or organic base in an aprotic polar or in an aprotic non-polar solvent such as DMF, THF or CH₂Cl₂ at
15 temperatures range between 0° to 65°C,


1D.b) The compounds of formula (1f) are obtained as described in 1B.b).

- E)** The compounds of general formula (I) wherein A is the radical (Ia) or (Ib), X₁ is -C(O) or -C(O)O-, and Y is
20 as above defined, can be obtained by a process comprising:

1E.a) reacting a compound of formula (IIIa') or (IIIb')



(IIIa')



(IIIb')

- 25 wherein Q is selected from a chlorine atom, a bromine atom, a iodine atom, mesyl, tosyl with a nitrate source such as silver nitrate, lithium nitrate, sodium nitrate, potassium nitrate, magnesium nitrate, calcium nitrate, iron nitrate, zinc nitrate or tetraalkylammonium nitrate (wherein alkyl

is C₁-C₁₀ alkyl) in a suitable organic solvent such as acetonitrile, tetrahydrofurane, methyl ethyl ketone, ethyl acetate, DMF, the reaction is carried out, in the dark, at a temperature ranges from room temperature to the boiling point temperature of the solvent. The preferred nitrate source is silver nitrate; and then

1E.b) removing the protective group with the methods known in the art; and optionally converting the resulting compound of general formula (I) into a pharmaceutically acceptable salt.

1E.c) The compounds of formula (IIIa') or (IIIb') as above defined are obtained by reacting compounds of formula (IIIa) and (IIIb) wherein P is as above defined, with compounds of formula (1h)

15 Act-C(O)-Y-Hal (1h)

or compounds of formula (1l)

Act-C(O)-O-Y-Hal (1l)

wherein Hal is an halogen atom and Act, Y are as above defined, in presence of an inorganic or organic base/DMAP in an aprotic polar/non-polar solvent such as DMF, THF or CH₂Cl₂ at temperatures range between 0° to 65°C or in a double phase system H₂O/Et₂O at temperatures range between 20° to 40°C; or in the presence of DMAP and a Lewis acid such as Sc(OTf)₃ or Bi(OTf)₃ in solvents such as DMF, CH₂Cl₂;

1E.d) The compounds of formula (1h)

Act-C(O)-Y-Hal (1h)

as above defined, are obtained by reacting commercially available (1c)


30 Act-H (1c)

with the commercially available compounds of formula (1d)

HO(O)C-Y-Hal (1d)

by conventional esterification reaction with condensing agents as DCC, EDAC.HCl as well known in the literature.

The compounds of formula (11)



as above defined, are obtained by reacting compounds of formula (1e)



which are commercially available or are obtained as described in 1B.c), with a compounds of formula (1f')





10 in presence of an inorganic or organic base in an aprotic polar/non-polar solvent such as DMF, THF or CH_2Cl_2 at temperatures range between 0° to 65°C or in a double phase system $\text{H}_2\text{O}/\text{Et}_2\text{O}$ at temperatures range between 20° to 40°C ;

1E.e) The compound of formula (IIIa), wherein P is an hydrogen atom, which is known as apraclonidine is commercially available or can be synthesized as described in US 4,517,199; the compound of formula IIIB, which is known as brimonidine, is commercially available or can be synthesised as according to the method described in US 3,890,319.

20 **F)** Alternatively, the compounds of general formula (I) wherein A is the radical (Ia) or (Ib), X_1 is $-\text{C(O)}$ or $-\text{C(O)O-}$, and Y is as above defined, can be obtained by a process comprising:

1F.a) reacting a compound of formula (IIIa'') or (IIIb'')

25




wherein


P is H or a amino protecting group such as t-butoxycarbonyl and those described in T. W. Greene "Protective groups in organic synthesis", Harvard University Press, 1980, with triflic anhydride/tetraalkylammonium nitrate salt in an
 5 aprotic polar/non-polar solvent such as DMF, THF or CH₂Cl₂ at temperatures range between -60° to 65°C;

1F.b) removing the protective group with the methods known in the art; and optionally converting the compound of formula (I) into a pharmaceutically acceptable salt.

10 **1F.c)** The compounds of formula (IIIa'') or (IIIb'') are obtained by reacting the compounds of formula (IIIa) or (IIIb) wherein P is as above defined, with compounds of formula (1m)



15 or with compounds of formula (1n)



wherein Act and Y are as above defined, in presence of a inorganic or organic base/DMAP in an aprotic polar/non-polar solvent such as DMF, THF or CH₂Cl₂ at temperatures
 20 range between 0° to 65°C or in a double phase system H₂O/Et₂O at temperatures range between 20° to 40°C; or in the presence of DMAP and a Lewis acid such as Sc(OTf)₃ or Bi(OTf)₃ in solvents such as DMF, CH₂Cl₂;


1F.d) The compounds of formula (1m)

25
$$\text{Act-C(O)-Y-OH (1m)}$$


are obtained by reacting commercially available (1c)



with the commercially available compounds of formula (1o)



30 by conventional esterification reaction with condensing agents as DCC, EDAC.HCl as well known in the literature; The compounds of formula (1n)



are obtained by reacting compounds of formula (1e)

Act-C(O)-Hal (1e)


which are commercially available or are obtained as described in 1B.c), with a compounds of formula(1j)

HO-Y-OH (1j)

- 5 in presence of an inorganic or organic base in an aprotic polar/non-polar solvent such as DMF, THF or CH₂Cl₂ at temperatures range between 0° to 65°C or in a double phase system H₂O/Et₂O at temperatures range between 20° to 40°C.

10

Scheme for Example 1



Reagents and conditions: a) AgNO₃, CH₃CN, r.t., 24 h; b) Triphosgene, Et₃N, benzene, 0 - 20 °C, 12 h; c) Et₃N, DMF, 40 h.

15

Abbreviations:

DMF = N,N-dimethylformamide

DCM = methylene chloride

Et₂O = diethyl ether

20


Et₃N = triethylamine

TFA = trifluoroacetic acid

Example 1


2-[5-Bromo-quinoxalin-6-ylimino]-imidazolidine-1-carboxylic
25 acid 2-nitrooxy-ethyl ester

2-Nitroxy-ethanol (B-13)



To a solution of 2-bromo-ethanol (2.5 g, 20 mmol) in dry CH₃CN (5.0 mL) was added to a solution of AgNO₃ (4.08 g, 24 mmol) in dry CH₃CN (20 mL) in dropwise. The solution was
 5 stirred for 24 h in darkness at room temperature. The reaction mixture was filtered and the collected solid was washed with CH₃CN. The filtrate was concentrated in vacuo and extracted with CH₂Cl₂. The organic layer was evaporated under vacuum to give Compound B-13 as a light yellow oil
 10 (1.07 g), with a similar NMR to that reported by Ziakas, G.N. et al, *Bioorg. Med. Chem.* **2005**, 13, 6485-6492 and WO2004/031372. The crude product was used in the next step without further purification.

2-Nitroxyethyl Chloroformate (B-14)




15

Compound B-13 (1.07g, 10 mmol) was added to a cold solution of triphosgene (1.485g, 5 mmol) in benzene (10 mL). The mixture was stirred at 0 °C for more than 20 min. A solution of Et₃N (1.01 g, 10 mmol) in benzene (5 mL) was added
 20 dropwise to the reaction mixture. The solution was warmed to room temperature and stirred overnight. The excess phosgene was removed by bubbling a stream of dry nitrogen through. The reaction mixture was evaporated and the residues was dissolved in Et₂O, and filtered to remove the
 25 salt. The collected solid was washed with Et₂O. The combined filtrate was evaporated under vacuum to give Compound B-14 as a light yellow oil (1.75 g) as light yellow oil. The crude product was used in the next step without further purification.

30

2-[5-Bromo-quinoxalin-6-ylimino]-imidazolidine-1-carboxylic acid 2-nitrooxy-ethyl ester

To a solution of A-3 (120 mg, 0.411 mmol) in DMF (8.0 mL) was added Et₃N (166 mg, 1.643 mmol), followed by addition
 5 of the solution of B-14 (140 mg, 0.822 mmol) in Et₂O (0.5 mL) dropwise. The solution was stirred for 4 h at 65 °C, and then for 40 h at room temperature. The mixture was evaporated under vacuum, and dissolved in CH₂Cl₂. The crude product was purified by preparative TLC (eluted with
 10 DCM/petroleum ether/EtOAc = 2:2:0.5) to give compound B as a white solid (59 mg, 34% yield). To determine whether the acylation occurred on the ring, as opposed to the exocyclic nitrogen between the rings as reported in analogous compounds by Kosasayama, A.; et al *Chem. Pharm. Bull. Jpn.*
 15 **1979**, 831-840: 2D ROSY ¹HNMR experiments showed interactions of the hydrogens on the ring and ethoxy as depicted below. Although this does not totally eliminate the possibility of the alternative regioisomer, molecular mechanics calculations indicate a higher energy
 20 conformation must be adopted to observe the interactions seen experimentally.



HPLC: 98.3 % Purity. Column: Luna 5μ C18 (2); Retention Time: 8.440 min; Mobile phase: methanol:0.01% aqueous TFA =
 25 25:75, Wavelength: 254 nm.


¹H NMR (400 MHz, CDCl₃): δ 3.97 (m, 4H, =N-CH₂-CH₂-NCO), 4.60 (t, J = 4.0 Hz, 2H, COOCH₂), 4.81 (t, J = 4.0 Hz, 2H, CH₂ONO₂), 8.09 (d, J = 9.6 Hz, 1H, Ar-H), 8.77 (d, J = 1.6

Hz, 1H, =N-CH=CH-N=), 8.91 (d, J = 1.6 Hz, 1H, =N-CH=CH-N=), 9.28 (d, J = 9.6 Hz, 1H, Ar-H), 10.35 (s, 1H, -NH-).

MS ($M+Na^+$): 447.2.

5

Scheme for Example 2




Reagents and conditions: a) $ZnNO_3$, DCC, CH_3CN , r.t.; b) Triphosgene, Et_3N , benzene, 0 - 20°C, 12 h; c) Et_3N , DMF, 64 h.

10

Example 2

2-[5-Bromo-quinoxalin-6-ylimino]-imidazolidine-1-carboxylic Acid 4-Nitroxy-butyl Ester

15 4-Nitroxy-butanol (A-11)




According to a preparation from *Environ. Sci. Technol.* **2000**, 34, 1197-1203, to a mixture of zinc nitrate hexahydrate (15 g) and acetonitrile (125 mL) was added 1,4-butanediol (20 mmol), followed by addition of N,N' -dicyclohexylcarbodiimide (10.3 g, 20 mmol). The reaction mixture was kept cold with ice-water bath, and then warmed and stirred at room temperature overnight. The white precipitate was filtered off, and the filtrate was

evaporated under vacuum to give Compound A-11 as a yellow oil (8.5 g). The crude product was used in the next step without further purification, but matched the cited reported NMR data.

- 5 ^1H NMR (400 MHz, CDCl_3): δ 1.69 (m, 2H, $-\text{CH}_2-$), 1.85 (m, 2H, $-\text{CH}_2-$), 3.69 (t, 2H, $J = 6.0$ Hz, CH_2OH), 4.50 (t, 2H, $J = 6.0$ Hz, CH_2ONO_2).

4-Nitroxybutyl Chloroformate (A-12)



- 10 Alcohol **A-11** (0.7g) was added to a cold solution of triphosgene (0.77 g) in benzene (5 mL). The mixture was stirred at 0°C for more than 20 min. The solution of Et_3N (0.53 g) in benzene (5 mL) was added dropwise to the reaction mixture. The mixture was warmed to room
- 15 temperature and stirred overnight. The excess phosgene was removed by bubbling a stream of dry nitrogen through. Then the reaction mixture was evaporated and the residues was dissolved in Et_2O , and filtered to remove the salt. The collected solid was washed with Et_2O . The combined filtrate
- 20 was evaporated under vacuum to give Compound A-12 as a light yellow oil (0.5 g). The crude product was used in the next step without further purification.

25 2-[5-Bromo-quinoxalin-6-ylimino]-imidazolidine-1-carboxylic Acid 4-Nitrooxy-butyl Ester

- To a solution of A-3 (96 mg) in DMF (7.0 mL) was added Et_3N (133 mg), followed by a solution of A-12 (260 mg) in Et_2O (0.5 mL) dropwise. The solution was stirred for 4 h at 65°C, and at room temperature for 64 h. The solvent was
- 30 evaporated under vacuum, and the residue was dissolved in

CH₂Cl₂. The crude product was purified by preparative TLC
(eluted with DCM/petroleum ether/EtOAc = 2:2:0.5) to give
compound A as a white solid (30 mg, 20% yield). The
regiochemistry of this product was assumed by analogy to
5 Example 1.

HPLC: 95.6 % Purity. Column: Luna 5μ C18 (2); Retention
Time: 2.576 min.; Mobile phase: methanol:0.01% aqueous TFA
= 48:52; Wavelength: 254 nm.


10

¹H NMR (400 MHz, CDCl₃): δ 1.90-1.93 (m, 4H, -CH₂-CH₂-),
3.90-3.99 (m, 4H, =N-CH₂-CH₂-NCO), 4.37 (s, 2H, COOCH₂),
4.56 (t, 2H, J = 6.0 Hz, CH₂ONO₂), 8.09 (d, J = 9.2 Hz, 1H,
Ar-H), 8.78 (d, J = 2.0 Hz, 1H, =N-CH=CH-N=), 8.92 (d, J =
15 2.0 Hz, 1H, =N-CH=CH-N=), 9.31 (d, J=9.2 Hz, 1H, Ar-H),
10.49 (s, 1H, -NH-).

MS: 453.

Claims

1. Compound of formula (I) and pharmaceutically acceptable salts or stereoisomers thereof,




5


(I)

wherein:

A is selected from



(Ia)




(Ib)

10

X_1 has the following meanings:

$-C(O)-$, $-C(O)O-$,



15 Y is a bivalent radical having the following meanings:

a)

- straight or branched C_1-C_{20} alkylene, preferably C_1-C_{10} , being optionally substituted with one or more of the substituents selected from the group consisting of: halogen


20 atoms, hydroxy, $-ONO_2$ or T_0 , wherein T_0 is

$-OC(O)(C_1-C_{10} \text{ alkyl})-ONO_2$ or $-O(C_1-C_{10} \text{ alkyl})-ONO_2$;


- cycloalkylene with 5 to 7 carbon atoms into cycloalkylene ring, the ring being optionally substituted with side chains T, wherein T is straight or branched alkyl with from

25 1 to 10 carbon atoms;

b)




c)



wherein n is an integer from 0 to 20,

n¹ is an integer from 1 to 20;

5 d)




wherein:

n¹ is as defined above and n² is an integer from 0 to 2;

X₂ = -OCO- or -COO- and R² is an hydrogen atom or CH₃;

10 e)




wherein:

n¹, n², R² and X₂ are as defined above;

Y¹ is -CH₂-CH₂- or -CH=CH-(CH₂)_{n2}-;

15 f)




wherein:

n¹ and R² are as defined above, R³ is H or -COCH₃;

20 with the proviso that when Y is selected from the bivalent radicals mentioned under b)-f), the -ONO₂ group is linked to a -(CH₂)_{n1} group;

g)




wherein X_3 is an oxygen atom or a sulphur atom,

n^3 is an integer from 1 to 6,

R^2 is as defined above;

h)



5


wherein:

n^4 is an integer from 0 to 10;

n^5 is an integer from 1 to 10;

R^4 , R^5 , R^6 , R^7 are the same or different, and are H or


10 straight or branched C_1 - C_4 alkyl, wherein the $-ONO_2$ group is linked to




wherein n^5 is as defined above;

Y^2 is an heterocyclic saturated, unsaturated or aromatic 5

15 or 6 members ring, containing one or more heteroatoms selected from nitrogen, oxygen, sulfur, and is selected from



20



2. Compound according to claim 1 wherein X_1 is $-C(O)-$ or
 5 $-C(O)O-$,


Y is a bivalent radical having the following meanings:

a)


- straight or branched C_1-C_{20} alkylene,

b)

10




c)



wherein n is an integer from 0 to 20,

n^1 is an integer from 1 to 20;

15 g)













wherein X_3 is an oxygen atom or a sulphur atom,

n^3 is an integer from 1 to 6,


R^2 is an hydrogen atom.

20

3. Compound according to claims 1 or 2 selected from:




(9)




(11)


(10)



(12)




(13)




(14)


5



(15)














(16)




(17)

10







(28)



(29)




(30)




(31)


5




(32)




(33)




(34)




(35)




(36)




(37)




(38)



(39)




(40)




(41)







5



(42)




(43)




5

(48)




(50)

(49)




(51)


5




(52)




(53)




(54)



(55)




(56)




(57)

5




(58)




(59)


10




(60)




(61)




(62)




(63)



(64)



(65)




(66)


4. Compound according to claims 1 to 3 for use as
5 medicament.
5. Use of compounds according to claims 1 to 3 for the preparation of medicaments for treating ocular diseases.
- 10 6. Use of compounds according to claims 1 to 3 for the preparation of medicaments for treating high intraocular pressure and glaucoma.
- 15 7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of general formula (I) and/or a salt or stereoisomer thereof as defined in claims 1-3.
- 20 8. A pharmaceutical composition according to claim 7 in a suitable form for the topical administration.
9. A pharmaceutical composition according to claims 7 and 8 for the treatment of ocular diseases.
- 25 10. A pharmaceutical composition according to claims 7-9 wherein the compound of general formula (I) is administered

as a solution, suspension or emulsion in an ophthalmically acceptable vehicle.

11. A pharmaceutical composition comprising a mixture of a
5 compound of formula (I) as defined in claim 1 and (i) a
beta-blocker or (ii) a carbonic anhydrase inhibitor or a
nitrooxyderivative thereof.



(Ia)



(Ib)